A new study has identified a key mechanism that explains why certain cancer therapies are ineffective for many patients. Researchers found that a specific protein complex, which varies significantly between individuals, can block the intended cell-killing action of common cancer drugs. This variation is linked to genetic differences in patients’ immune systems and tumor microenvironments. The discovery, made through advanced genomic analysis of patient tumor samples, points toward the need for more personalized treatment approaches. Future work will focus on developing diagnostic tests to screen for this protein complex before treatment begins. Read the full article at: https://www.sciencedaily.com/releases/2026/03/260326075550.htm